Study #2023-0607
Phase 1b/2a study of GNS561 in combination with Trametinib in advanced KRAS mutated Cholangiocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
GNS561 + Trametinib
Description
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cholangiocarcinoma
Study phase:
Physician name:
Milind Javle
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.